The University of Texas MD Anderson Cancer Center has unveiled plans to acquire Bellicum Pharmaceuticals’ approximately 60,000-square-foot Houston facility, including manufacturing, office and laboratory space, for $15 million.   As part of the deal, Bellicum will also enter into a master services agreement with MD Anderson. MD Anderson will operate the Houston facility for its own internal programs as well as to manufacture Bellicum’s GoCAR and other cellular therapy programs for clinical...